Apr. 28 at 3:34 PM
$CABA correct. The abstract discussing the CAR-T results for 4 patient without chemotherapy preconditioning is a big deal.
All patients had clinically meaningful PDAI score reductions by Week 4, maintained through Week 12. The 3 patients with full B-cell depletion improved more, and anti-DSG3/anti-DSG1 autoantibodies fell in parallel with clinical improvement.
Safety was solid as well - no dose-limiting toxicity, no ICANS, and only one Grade 1 CRS event, which went away with antipyretics and tocilizumab.
My big takeaway from this abstract is that
$CABA may be able to make CAR-T work in autoimmune disease without the chemo prep. That is very significant because chemo preconditioning is one of the biggest barriers to using CAR-T broadly in non-cancer patients. It hugely lowers costs and opens up all sorts of new access to the treatment.
This is still early data and we need readouts with more patience, but it’s really good stuff. It’s available and the press is not reporting it.
